8-Methyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-Methyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine
• 英文别名: 8-methyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine
• 化学式: C₁₂H₂₀N₆
• 分子量: 248.33
• InChiKey: HKJNEZSCKHWBJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  81.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] TARGETED THERAPEUTICS<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLES
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015143004A9

  公开（公告）日：2016-09-29
• [EN] TARGETED THERAPEUTICS<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLÉS
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2013158644A2

  公开（公告）日：2013-10-24

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.